Nina Raben

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2164389/publications.pdf

Version: 2024-02-01

45 papers	9,344 citations	136950 32 h-index	233421 45 g-index
45 all docs	45 docs citations	45 times ranked	18212 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	9.1	4,701
2	The Nutrient-Responsive Transcription Factor TFE3 Promotes Autophagy, Lysosomal Biogenesis, and Clearance of Cellular Debris. Science Signaling, 2014, 7, ra9.	3.6	486
3	Autophagy in lysosomal storage disorders. Autophagy, 2012, 8, 719-730.	9.1	345
4	TFEB and TFE3: Linking Lysosomes to Cellular Adaptation to Stress. Annual Review of Cell and Developmental Biology, 2016, 32, 255-278.	9.4	308
5	Suppression of autophagy in skeletal muscle uncovers the accumulation of ubiquitinated proteins and their potential role in muscle damage in Pompe disease. Human Molecular Genetics, 2008, 17, 3897-3908.	2.9	291
6	Dysfunction of endocytic and autophagic pathways in a lysosomal storage disease. Annals of Neurology, 2006, 59, 700-708.	5.3	286
7	Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease. EMBO Molecular Medicine, 2013, 5, 691-706.	6.9	273
8	Targeted Disruption of the Acid Î±-Glucosidase Gene in Mice Causes an Illness with Critical Features of Both Infantile and Adult Human Glycogen Storage Disease Type II. Journal of Biological Chemistry, 1998, 273, 19086-19092.	3.4	250
9	TFEB and TFE3 cooperate in the regulation of the innate immune response in activated macrophages. Autophagy, 2016, 12, 1240-1258.	9.1	230
10	Autophagy and Mistargeting of Therapeutic Enzyme in Skeletal Muscle in Pompe Disease. Molecular Therapy, 2006, 14, 831-839.	8.2	169
11	Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. American Journal of Medical Genetics Part A, 1998, 79, 69-72.	2.4	165
12	Pompe disease: from pathophysiology to therapy and back again. Frontiers in Aging Neuroscience, 2014, 6, 177.	3.4	147
13	Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorderâ€"murine Pompe disease. Autophagy, 2010, 6, 1078-1089.	9.1	140
14	Correction of the Enzymatic and Functional Deficits in a Model of Pompe Disease Using Adeno-associated Virus Vectors. Molecular Therapy, 2002, 5, 571-578.	8.2	127
15	Pompe Disease: From Basic Science to Therapy. Neurotherapeutics, 2018, 15, 928-942.	4.4	127
16	Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: â€œTo See a World in a Grain of Sandâ€¦â€• Autophagy, 2007, 3, 546-552.	9.1	102
17	Carbohydrate-remodelled acid Î±-glucosidase with higher affinity for the cation-independent mannose 6-phosphate receptor demonstrates improved delivery to muscles of Pompe mice. Biochemical Journal, 2005, 389, 619-628.	3.7	96
18	Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease. Autophagy, 2015, 11, 385-402.	9.1	93

#	Article	IF	Citations
19	Modulation of <scp>mTOR</scp> signaling as a strategy for the treatment of Pompe disease. EMBO Molecular Medicine, 2017, 9, 353-370.	6.9	83
20	Chapter 21 Monitoring Autophagy in Lysosomal Storage Disorders. Methods in Enzymology, 2009, 453, 417-449.	1.0	82
21	Conjugation of Mannose 6-Phosphate-containing Oligosaccharides to Acid Î±-Glucosidase Improves the Clearance of Glycogen in Pompe Mice. Journal of Biological Chemistry, 2004, 279, 50336-50341.	3.4	79
22	A model of mRNA splicing in adult lysosomal storage disease (glycogenosis type II). Human Molecular Genetics, 1996, 5, 995-1000.	2.9	72
23	The African Origin of the Common Mutation in African American Patients with Glycogen-Storage Disease Type II. American Journal of Human Genetics, 1998, 62, 991-994.	6.2	60
24	Improved efficacy of a next-generation ERT in murine Pompe disease. JCI Insight, 2019, 4, .	5.0	57
25	The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients. Acta Neuropathologica Communications, 2014, 2, 2.	5.2	55
26	Pompe Disease: New Developments in an Old Lysosomal Storage Disorder. Biomolecules, 2020, 10, 1339.	4.0	52
27	When more is less: Excess and deficiency of autophagy coexist in skeletal muscle in Pompe disease. Autophagy, 2009, 5, 111-113.	9.1	51
28	Restoration of muscle functionality by genetic suppression of glycogen synthesis in a murine model of Pompe disease. Human Molecular Genetics, 2010, 19, 684-696.	2.9	51
29	Fiber Type Conversion by PGC-1Î± Activates Lysosomal and Autophagosomal Biogenesis in Both Unaffected and Pompe Skeletal Muscle. PLoS ONE, 2010, 5, e15239.	2.5	48
30	Therapeutic Benefit of Autophagy Modulation in Pompe Disease. Molecular Therapy, 2018, 26, 1783-1796.	8.2	46
31	Intravenous Injection of an AAV-PHP.B Vector Encoding Human Acid Î±-Glucosidase Rescues Both Muscle and CNS Defects in Murine Pompe Disease. Molecular Therapy - Methods and Clinical Development, 2019, 12, 233-245.	4.1	38
32	Impaired autophagy: The collateral damage of lysosomal storage disorders. EBioMedicine, 2021, 63, 103166.	6.1	36
33	Modulation of glycogen synthesis by RNA interference: towards a new therapeutic approach for glycogenosis type II. Human Molecular Genetics, 2008, 17, 3876-3886.	2.9	35
34	Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches. Molecular Genetics and Metabolism, 2009, 96, 208-217.	1.1	35
35	Pompe disease: Shared and unshared features of lysosomal storage disorders. Rare Diseases (Austin,) Tj ETQq1 1 0.784314 rgBT /Ove	1.8	29
36	Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease. Molecular Therapy - Methods and Clinical Development, 2020, 18, 199-214.	4.1	26

#	Article	IF	Citations
37	Novel degenerative and developmental defects in a zebrafish model of mucolipidosis type IV. Human Molecular Genetics, 2017, 26, 2701-2718.	2.9	16
38	SnapShot: Lysosomal Storage Diseases. Cell, 2020, 180, 602-602.e1.	28.9	16
39	Atg5flox-Derived Autophagy-Deficient Model of Pompe Disease: Does It Tell the Whole Story?. Molecular Therapy - Methods and Clinical Development, 2017, 7, 11-14.	4.1	12
40	Pros and cons of different ways to address dysfunctional autophagy in Pompe disease. Annals of Translational Medicine, 2019, 7, 279-279.	1.7	8
41	Pompe disease: how to solve many problems with one solution. Annals of Translational Medicine, 2018, 6, 313-313.	1.7	6
42	Nutritional co-therapy with 1,3-butanediol and multi-ingredient antioxidants enhances autophagic clearance in Pompe disease. Molecular Genetics and Metabolism, 2022, 137, 228-240.	1.1	6
43	Chemoenzymatic glycan-selective remodeling of a therapeutic lysosomal enzyme with high-affinity M6P-glycan ligands. Enzyme substrate specificity is the name of the game. Chemical Science, 2021, 12, 12451-12462.	7.4	5
44	New therapies for Pompe disease: are we closer to a cure?. Lancet Neurology, The, 2021, 20, 973-975.	10.2	3
45	Editorial for focused issue â€œPompe disease: from basics to current and emerging therapiesâ€• Annals of Translational Medicine, 2019, 7, 275-275.	1.7	1